Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Form 144 notice for Travere Therapeutics, Inc. (TVTX) reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $250,000.00. The filing states the shares were acquired and will be sold on 09/22/2025 via a stock option exercise from the issuer, with payment in cash. The issuer's outstanding shares are listed as 89,138,673. The filer reports no securities sold in the past three months. Several identifying fields (filer CIK and contact details) are blank in the provided text.
Travere Therapeutics reports that the U.S. FDA has informed the company an advisory committee is no longer needed for its supplemental new drug application (sNDA) for FILSPARI in focal segmental glomerulosclerosis (FSGS). The sNDA remains under review with a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026.
If approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disorder that causes protein in the urine and progressive kidney damage. The filing highlights Phase 3 DUPLEX and Phase 2 DUET studies, where FILSPARI showed rapid, superior and sustained reductions in proteinuria versus maximally dosed irbesartan in adult and pediatric patients, and a safety profile comparable to irbesartan.
The DUPLEX study showed statistically significant and clinically meaningful proteinuria remission at 36 weeks that was durable through 2 years, and patients achieving partial or complete remission had a 67% to 77% lower risk of kidney failure. FILSPARI is already fully approved in the U.S. and EU to slow kidney function decline in adults with IgA nephropathy.
Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, sold 470 shares of the company's common stock on 08/27/2025 at a price of $17.31 per share under a written plan intended to satisfy Rule 10b5-1(c). The filing reports 92,656 shares beneficially owned by Mr. Cline after the transaction.
The sale was executed pursuant to a 10b5-1 plan adopted on May 28, 2025 and included additional shares sold to cover the tax obligation arising from the vesting of performance-based restricted stock units that vested in May 2025. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/28/2025.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 8,876,000 shares of Travere Therapeutics (TVTX), representing 9.96% of the outstanding common stock. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares. Mr. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The percent ownership is calculated using 89,138,673 shares outstanding as of July 31, 2025, per the issuers SEC filing.
Selected financial highlights (three and six months ended June 30, 2025): Total revenue was $114.4 million for Q2 and $196.2 million for the six months. Net product sales were $94.8 million in Q2 (FILSPARI $71.9M, tiopronin $23.0M) vs. $52.2M a year ago. License and collaboration revenue included a $17.5 million regulatory milestone. Operating loss for the quarter was $12.7M; six-month net loss was $53.98M (basic/diluted loss per share YTD $0.61). Cash and cash equivalents were $75.2M and available-for-sale marketable debt securities were $244.4M (total liquid investments $319.5M). Total assets were $555.3M, total liabilities $522.6M, and stockholders' equity $32.7M.
Operational and programmatic items: FILSPARI previously received full U.S. approval (Sept 5, 2024) and the European conditional MA converted to a standard MA in April 2025, triggering the $17.5M milestone in May 2025. The company submitted an sNDA seeking FSGS approval; the FDA accepted the sNDA and set a PDUFA date of Jan 13, 2026 and plans an advisory committee. Pegtibatinase enrollment is on a voluntary pause due to manufacturing scale-up issues. Renalys licensing and other collaborations remain active.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
